Mannkind Corporation

Alfred Mann

Anders Hasager Boss

Richard Petrucci

Campbell Howard

Scott Mclean

Scott McLean

Benoit Adamo

Chad C Smutney

P Spencer Kinsey

John M Polidoro

Carl R Sahi

Peter Richardson

Robert A Baughman

Anthony Bryant

Elizabeth Potocka

Tom He

Dennis O Overfield

Anthony J Bryant

Dennis Overfield

Dennis Overfileld

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Use of ultrarapid acting insulin

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Dry powder inhaler and system for drug delivery

Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content

Growing community of inventors

Valencia, CA, United States of America

Alfred Mann